The role of histone deacetylase 6 (HDAC6) in neurodegeneration

References

• Li G, Jiang H, Chang M, Xie H, Hu L. HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases. J Neurol Sci. 2011;304(1–2):1–8.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li N, Caron C, et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 2003;22(5):1168–1179.
   PubMed Web of Science ®Google Scholar
• Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005;18(5):601–607.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yuan Z, Zhang Y, et al. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell. 2007;27(2):197–213.
   PubMed Web of Science ®Google Scholar
• Ding G, Liu HD, Huang Q, et al. HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity. FEBS Lett. 2013;587(7):880–886.
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003;115(6):727–738.
   PubMed Web of Science ®Google Scholar
• Parmigiani RB, Xu WS, Venta-Perez G, et al. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci U S A. 2008;105(28):9633–9638.
   PubMed Web of Science ®Google Scholar
• Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997;389(6649):349–352.
   PubMed Web of Science ®Google Scholar
• d’Ydewalle C, Bogaert E, Van Den Bosch L. HDAC6 at the intersection of neuroprotection and neurodegeneration. Traffic. 2012;13(6):771–779.
   PubMed Web of Science ®Google Scholar
• de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs):characterization of the classical HDAC family. Biochem J. 2003;370(Pt 3):737–749.
   PubMed Web of Science ®Google Scholar
• Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795–800.
   PubMed Web of Science ®Google Scholar
• Polo SE, Almouzni G. Histone metabolic pathways and chromatin assembly factors as proliferation markers. Cancer Lett. 2005;220(1):1–9.
   Web of Science ®Google Scholar
• Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011;3(2):166–179.
   PubMed Web of Science ®Google Scholar
• Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res. 2009;15(12):3958–3969.
   PubMed Web of Science ®Google Scholar
• Thaler F, Mercurio C. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are, and what will be next. ChemMedChem. 2014;9(3):523–526.
   PubMed Web of Science ®Google Scholar
• Bertos NR, Gilquin B, Chan GK, Yen TJ, Khochbin S, Yang XJ. Role of the tetradecapeptide repeat domain of human histone deacetylase 6 in cytoplasmic retention. J Biol Chem. 2004;279(46):48246–48254.
   PubMed Web of Science ®Google Scholar
• Westermann S, Weber K. Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol. 2003;4(12):938–947.
   PubMed Web of Science ®Google Scholar
• Maruta H, Greer K, Rosenbaum JL. The acetylation of α-tubulin and its relationship to the assembly and disassembly of microtubules. J Cell Biol. 1986;103(2):571–579.
   PubMed Web of Science ®Google Scholar
• Janke C, Bulinski JC. Post-translational regulation of the microtubule cytoskeleton: mechanisms and functions. Nat Rev Mol Cell Biol. 2011;12(12):773–786.
   PubMed Web of Science ®Google Scholar
• Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubule-associated deacetylase. Nature. 2002;417(6887):455–458.
   PubMed Web of Science ®Google Scholar
• Matsuyama A, Shimazu T, Sumida Y, et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 2002;21(24):6820–6831.
   PubMed Web of Science ®Google Scholar
• Zilberman Y, Ballestrem C, Carramusa L, Mazitschek R, Khochbin S, Bershadsky A. Regulation of microtubule dynamics by inhibition of the tubulin deacetylase HDAC6. J Cell Sci. 2009;122(Pt 19):3531–3541.
   PubMed Web of Science ®Google Scholar
• Brinkley BR. Microtubule organizing centers. Annu Rev Cell Biol. 1985;1:145–172.
   PubMedGoogle Scholar
• Conde C, Caceres A. Microtubule assembly, organization, and dynamics in axons and dendrites. Nat Rev Neurosci. 2009;10(5):319–332.
   PubMed Web of Science ®Google Scholar
• Karki S, Holzbaur EL. Cytoplasmic dynein and dynactin in cell division and intracellular transport. Curr Opin Cell Biol. 1999;11(1):45–53.
   Web of Science ®Google Scholar
• Hirokawa N. Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science. 1998;279(5350):519–526.
   PubMed Web of Science ®Google Scholar
• Reed NA, Cai D, Blasius TL, et al. Microtubule acetylation promotes kinesin-1 binding and transport. Curr Biol. 2006;16(21):2166–2172.
   Web of Science ®Google Scholar
• Chen S, Owens GC, Makarenkova H, Edelman DB. HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS One. 2010;5(5):e10848.
   PubMed Web of Science ®Google Scholar
• Kopito RR. The missing linker: an unexpected role for a histone deacetylase. Mol Cell. 2003;12(6):1349–1351.
   Web of Science ®Google Scholar
• Dompierre JP, Godin JD, Charrin BC, et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington’s disease by increasing tubulin acetylation. J Neurosci. 2007;27(13):3571–3583.
   PubMed Web of Science ®Google Scholar
• Chen S, Owens GC, Crossin KL, Edelman DB. Serotonin stimulates mitochondrial transport in hippocampal neurons. Mol Cell Neurosci. 2007;36(4):472–483.
   PubMed Web of Science ®Google Scholar
• Wood ZA, Schroder E, Robin Harris J, Poole LB. Structure, mechanism, and regulation of peroxiredoxins. Trends Biochem Sci. 2003;28(1):32–40.
   PubMed Web of Science ®Google Scholar
• Moon JC, Kim GM, Kim EK, et al. Reversal of 2-Cys peroxiredoxin oligomerization by sulfiredoxin. Biochem Biophys Res Commun. 2013;432(2):291–295.
   Web of Science ®Google Scholar
• Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology. 2010;129(2):154–169.
   PubMed Web of Science ®Google Scholar
• Amor S, Woodroofe MN. Innate and adaptive immune responses in neurodegeneration and repair. Immunology. 2014;141(3):287–291.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T-cells. Nat Immunol. 2003;4(4):330–336.
   PubMed Web of Science ®Google Scholar
• Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 2011;32(7):335–343.
   PubMed Web of Science ®Google Scholar
• De Zoeten EF, Wang L, Butler K, et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3+ T-regulatory cells. Mol Cell Biol. 2011;31(10):2066–2078.
   PubMed Web of Science ®Google Scholar
• Liesz A, Zhou W, Na SY, et al. Boosting regulatory T-cells limits neuroinflammation in permanent cortical stroke. J Neurosci. 2013;33(44):17350–17362.
   Web of Science ®Google Scholar
• Kleinewietfeld M, Hafler DA. Regulatory T-cells in autoimmune neuroinflammation. Immunol Rev. 2014;259(1):231–244.
   PubMed Web of Science ®Google Scholar
• Buchner J. Hsp90 and co. – a holding for folding. Trends Biochem Sci. 1999;24(4):136–141.
   Web of Science ®Google Scholar
• Ali A, Bharadwaj S, O’Carroll R, Ovsenek N. HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes. Mol Cell Biol. 1998;18(9):4949–4960.
   PubMed Web of Science ®Google Scholar
• Boyault C, Zhang Y, Fritah S, et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev. 2007;21(17):2172–2181.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang T, Schwartz SJ, Sun D. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective, and more potential. Drug Resist Updat. 2009;12(1–2):17–27.
   PubMed Web of Science ®Google Scholar
• Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6–Hsp90 chaperone axis. Cell Death Differ. 2011;18(12):1904–1913.
   PubMed Web of Science ®Google Scholar
• Gravina GL, Marampon F, Muzi P, et al. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer. Endocr Relat Cancer. 2013;20(3):321–337.
   Web of Science ®Google Scholar
• Li D, Sun X, Zhang L, et al. Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells. Protein Cell. 2014;5(3):214–223.
   Web of Science ®Google Scholar
• Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature. 2003;426(6968):895–899.
   PubMed Web of Science ®Google Scholar
• Stoppini M, Andreola A, Foresti G, Bellotti V. Neurodegenerative diseases caused by protein aggregation: a phenomenon at the borderline between molecular evolution and ageing. Pharmacol Res. 2004;50(4):419–431.
   Web of Science ®Google Scholar
• De Duve C. The lysosome. Sci Am. 1963;208:64–72.
   PubMedGoogle Scholar
• Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004;6(4):463–477.
   PubMed Web of Science ®Google Scholar
• Massey AC, Zhang C, Cuervo AM. Chaperone-mediated autophagy in aging and disease. Curr Top Dev Biol. 2006;73:205–235.
   PubMed Web of Science ®Google Scholar
• Boyault C, Gilquin B, Zhang Y, et al. HDAC6–p97/VCP controlled polyubiquitin chain turnover. EMBO J. 2006;25(14):3357–3366.
   Web of Science ®Google Scholar
• Bagola K, Mehnert M, Jarosch E, Sommer T. Protein dislocation from the ER. Biochim Biophys Acta. 2011;1808(3):925–936.
   PubMed Web of Science ®Google Scholar
• Wolf DH, Stolz A. The Cdc48 machine in endoplasmic reticulum associated protein degradation. Biochim Biophys Acta. 2012;1823(1):117–124.
   PubMed Web of Science ®Google Scholar
• Seigneurin-Berny D, Verdel A, Curtet S, et al. Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways. Mol Cell Biol. 2001;21(23):8035–8044.
   PubMed Web of Science ®Google Scholar
• Kopito RR. Aggresomes, inclusion bodies, and protein aggregation. Trends Cell Biol. 2000;10(12):524–530.
   PubMed Web of Science ®Google Scholar
• Zeng XC, Bhasin S, Wu X, et al. Hsp70 dynamics in vivo: effect of heat shock and protein aggregation. J Cell Sci. 2004;117(Pt 21):4991–5000.
   Web of Science ®Google Scholar
• Waza M, Adachi H, Katsuno M, et al. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. J Mol Med (Berl). 2006;84(8):635–646.
   Web of Science ®Google Scholar
• Pandey UB, Nie Z, Batlevi Y, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature. 2007;447(7146):859–863.
   PubMed Web of Science ®Google Scholar
• Lee JY, Koga H, Kawaguchi Y, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J. 2010;29(5):969–980.
   PubMed Web of Science ®Google Scholar
• Mizushima N, Ohsumi Y, Yoshimori T. Autophagosome formation in mammalian cells. Cell Struct Funct. 2002;27(6):421–429.
   PubMed Web of Science ®Google Scholar
• Iwata A, Riley BE, Johnston JA, Kopito RR. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem. 2005;280(48):40282–40292.
   PubMed Web of Science ®Google Scholar
• Liebl D, Griffiths G. Transient assembly of F-actin by phagosomes delays phagosome fusion with lysosomes in cargo-overloaded macrophages. J Cell Sci. 2009;122(Pt 16):2935–2945.
   Web of Science ®Google Scholar
• Boyault C, Sadoul K, Pabion M, Khochbin S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene. 2007;26(37):5468–5476.
   PubMed Web of Science ®Google Scholar
• Anderson P, Kedersha N. RNA granules. J Cell Biol. 2006;172(6):803–808.
   PubMed Web of Science ®Google Scholar
• Mazroui R, Di Marco S, Kaufman RJ, Gallouzi IE. Inhibition of the ubiquitin–proteasome system induces stress granule formation. Mol Biol Cell. 2007;18(7):2603–2618.
   Web of Science ®Google Scholar
• Kwon S, Zhang Y, Matthias P. The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response. Genes Dev. 2007;21(24):3381–3394.
   PubMed Web of Science ®Google Scholar
• Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol. 2011;2011:875824.
   PubMed Web of Science ®Google Scholar
• Jochems J, Boulden J, Lee BG, et al. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability. Neuropsychopharmacology. 2014;39(2):389–400.
   PubMed Web of Science ®Google Scholar
• Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012;119(11):2579–2589.
   PubMed Web of Science ®Google Scholar
• Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787–795.
   PubMed Web of Science ®Google Scholar
• De Vos KJ, Grierson AJ, Ackerley S, Miller CC. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci. 2008;31:151–173.
   PubMed Web of Science ®Google Scholar
• Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med. 2004;10 Suppl:S10–S17.
   Web of Science ®Google Scholar
• Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science. 2002;296(5575):1991–1995.
   PubMed Web of Science ®Google Scholar
• Terwel D, Dewachter I, Van Leuven F. Axonal transport, tau protein, and neurodegeneration in Alzheimer’s disease. Neuromolecular Med. 2002;2(2):151–165.
   PubMed Web of Science ®Google Scholar
• Ding H, Dolan PJ, Johnson GV. Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem. 2008;106(5):2119–2130.
   PubMed Web of Science ®Google Scholar
• Cook C, Carlomagno Y, Gendron TF, et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet. 2014;23(1):104–116.
   PubMed Web of Science ®Google Scholar
• Cook C, Gendron TF, Scheffel K, et al. Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation. Hum Mol Genet. 2012;21(13):2936–2945.
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu C, Wu J, et al. Tubastatin A/ACY-1215 improves cognition in Alzheimer’s disease transgenic mice. J Alzheimers Dis. Epub May 20, 2014.
   Google Scholar
• Noack M, Leyk J, Richter-Landsberg C. HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes. Glia. 2014;62(4):535–547.
   Web of Science ®Google Scholar
• Kim C, Choi H, Jung ES, et al. HDAC6 inhibitor blocks amyloid β-induced impairment of mitochondrial transport in hippocampal neurons. PLoS One. 2012;7(8):e42983.
   Web of Science ®Google Scholar
• Perez M, Santa-Maria I, Gomez de Barreda E, et al. Tau – an inhibitor of deacetylase HDAC6 function. J Neurochem. 2009;109(6):1756–1766.
   Web of Science ®Google Scholar
• Odagiri S, Tanji K, Mori F, et al. Brain expression level and activity of HDAC6 protein in neurodegenerative dementia. Biochem Biophys Res Commun. 2013;430(1):394–399.
   PubMed Web of Science ®Google Scholar
• Zhang L, Sheng S, Qin C. The role of HDAC6 in Alzheimer’s disease. J Alzheimers Dis. 2013;33(2):283–295.
   PubMed Web of Science ®Google Scholar
• Cecarini V, Bonfili L, Cuccioloni M, et al. Crosstalk between the ubiquitin–proteasome system and autophagy in a human cellular model of Alzheimer’s disease. Biochim Biophys Acta. 2012;1822(11):1741–1751.
   Web of Science ®Google Scholar
• Selenica ML, Benner L, Housley SB, et al. Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alzheimers Res Ther. 2014;6(1):12.
   PubMed Web of Science ®Google Scholar
• Govindarajan N, Rao P, Burkhardt S, et al. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer’s disease. EMBO Mol Med. 2013;5(1):52–63.
   PubMed Web of Science ®Google Scholar
• McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci. 2002;16(11):2136–2148.
   Web of Science ®Google Scholar
• Su M, Shi JJ, Yang YP, et al. HDAC6 regulates aggresome–autophagy degradation pathway of α-synuclein in response to MPP+-induced stress. J Neurochem. 2011;117(1):112–120.
   PubMed Web of Science ®Google Scholar
• Du G, Liu X, Chen X, et al. Drosophila histone deacetylase 6 protects dopaminergic neurons against α-synuclein toxicity by promoting inclusion formation. Mol Biol Cell. 2010;21(13):2128–2137.
   Web of Science ®Google Scholar
• Olzmann JA, Li L, Chudaev MV, et al. Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. J Cell Biol. 2007;178(6):1025–1038.
   PubMed Web of Science ®Google Scholar
• Lee JY, Nagano Y, Taylor JP, Lim KL, Yao TP. Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy. J Cell Biol. 2010;189(4):671–679.
   PubMed Web of Science ®Google Scholar
• Gunawardena S, Her LS, Brusch RG, et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron. 2003;40(1):25–40.
   Web of Science ®Google Scholar
• Bobrowska A, Paganetti P, Matthias P, Bates GP. Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington’s disease. PLoS One. 2011;6(6):e20696.
   PubMed Web of Science ®Google Scholar
• Chopra V, Quinti L, Kim J, et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington’s disease mouse models. Cell Rep. 2012;2(6):1492–1497.
   PubMed Web of Science ®Google Scholar
• Kim SH, Shanware NP, Bowler MJ, Tibbetts RS. Amyotrophic lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA. J Biol Chem. 2010;285(44):34097–34105.
   PubMed Web of Science ®Google Scholar
• Fiesel FC, Schurr C, Weber SS, Kahle PJ. TDP-43 knockdown impairs neurite outgrowth dependent on its target histone deacetylase 6. Mol Neurodegener. 2011;6:64.
   PubMed Web of Science ®Google Scholar
• Alami NH, Smith RB, Carrasco MA, et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014;81(3):536–543.
   PubMed Web of Science ®Google Scholar
• Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68(5):857–864.
   PubMed Web of Science ®Google Scholar
• Blokhuis AM, Groen EJ, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125(6):777–794.
   PubMed Web of Science ®Google Scholar
• Taes I, Timmers M, Hersmus N, et al. Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. Hum Mol Genet. 2013;22(9):1783–1790.
   PubMed Web of Science ®Google Scholar
• Yoo YE, Ko CP. Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2011;231(1):147–159.
   PubMed Web of Science ®Google Scholar
• Gal J, Chen J, Barnett KR, Yang L, Brumley E, Zhu H. HDAC6 regulates mutant SOD1 aggregation through two SMIR motifs and tubulin acetylation. J Biol Chem. 2013;288(21):15035–15045.
   Web of Science ®Google Scholar
• Deng HX, Chen W, Hong ST, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011;477(7363):211–215.
   PubMed Web of Science ®Google Scholar
• Zhao W, Beers DR, Liao B, Henkel JS, Appel SH. Regulatory T-lymphocytes from ALS mice suppress microglia and effector T-lymphocytes through different cytokine-mediated mechanisms. Neurobiol Dis. 2012;48(3):418–428.
   Web of Science ®Google Scholar
• Henkel JS, Beers DR, Wen S, et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5(1):64–79.
   PubMed Web of Science ®Google Scholar
• Liu D, Liu C, Li J, et al. Proteomic analysis reveals differentially regulated protein acetylation in human amyotrophic lateral sclerosis spinal cord. PLoS One. 2013;8(12):e80779.
   Web of Science ®Google Scholar
• Hahnen E, Eyupoglu IY, Brichta L, et al. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem. 2006;98(1):193–202.
   PubMed Web of Science ®Google Scholar
• Avila AM, Burnett BG, Taye AA, et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest. 2007;117(3):659–671.
   PubMed Web of Science ®Google Scholar
• Evans MC, Cherry JJ, Androphy EJ. Differential regulation of the SMN2 gene by individual HDAC proteins. Biochem Biophys Res Commun. 2011;414(1):25–30.
   PubMed Web of Science ®Google Scholar
• Hofmann Y, Lorson CL, Stamm S, Androphy EJ, Wirth B. Htra2-β1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc Natl Acad Sci U S A. 2000;97(17):9618–9623.
   PubMed Web of Science ®Google Scholar
• Malik B, Nirmalananthan N, Bilsland LG, et al. Absence of disturbed axonal transport in spinal and bulbar muscular atrophy. Hum Mol Genet. 2011;20(9):1776–1786.
   Web of Science ®Google Scholar
• Dale JM, Shen H, Barry DM, et al. The spinal muscular atrophy mouse model, SMAΔ7, displays altered axonal transport without global neurofilament alterations. Acta Neuropathol. 2011;122(3):331–341.
   Web of Science ®Google Scholar
• Department of Molecular Genetics. Inherited Peripheral Neuropathies Mutation Database (webpage on Internet). Updated 17 February 2011. Available from http://www.molgen.ua.ac.be/CMTMutations/. Accessed August 14, 2014.
   Google Scholar
• Brownlees J, Ackerley S, Grierson AJ, et al. Charcot–Marie–Tooth disease neurofilament mutations disrupt neurofilament assembly and axonal transport. Hum Mol Genet. 2002;11(23):2837–2844.
   Web of Science ®Google Scholar
• Ackerley S, James PA, Kalli A, French S, Davies KE, Talbot K. A mutation in the small heat-shock protein HSPB1 leading to distal hereditary motor neuronopathy disrupts neurofilament assembly and the axonal transport of specific cellular cargoes. Hum Mol Genet. 2006;15(2):347–354.
   Web of Science ®Google Scholar
• Baloh RH, Schmidt RE, Pestronk A, Milbrandt J. Altered axonal mitochondrial transport in the pathogenesis of Charcot–Marie–Tooth disease from mitofusin 2 mutations. J Neurosci. 2007;27(2):422–430.
   PubMed Web of Science ®Google Scholar
• Zhai J, Lin H, Julien JP, Schlaepfer WW. Disruption of neurofilament network with aggregation of light neurofilament protein: a common pathway leading to motor neuron degeneration due to Charcot–Marie–Tooth disease-linked mutations in NFL and HSPB1. Hum Mol Genet. 2007;16(24):3103–3116.
   Web of Science ®Google Scholar
• Lv H, Wang L, Li W, et al. Mitofusin 2 gene mutation causing early-onset CMT2A with different progressive courses. Clin Neuropathol. 2013;32(1):16–23.
   Web of Science ®Google Scholar
• Lee SM, Olzmann JA, Chin LS, Li L. Mutations associated with Charcot–Marie–Tooth disease cause SIMPLE protein mislocalization and degradation by the proteasome and aggresome–autophagy pathways. J Cell Sci. 2011;124(Pt 19):3319–3331.
   Web of Science ®Google Scholar
• Lee SM, Chin LS, Li L. Protein misfolding and clearance in demyelinating peripheral neuropathies: therapeutic implications. Commun Integr Biol. 2012;5(1):107–110.
   PubMedGoogle Scholar
• d’Ydewalle C, Krishnan J, Chiheb DM, et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot–Marie–Tooth disease. Nat Med. 2011;17(8):968–974.
   PubMed Web of Science ®Google Scholar